| ||||||||||||||
|
|
|||||||||||||
Department of Anesthesia; Wolfson Medical Center; Holon, Israel; tezri{at}netvision.net.il
In Response:
Dr. Neustein1 raises important concerns regarding the use of lidocaine for spinal anesthesia. The increasing number of day surgery cases requires availability of a short-acting, yet safe, local anesthetic if spinal anesthesia is employed in outpatients and no one drug meets all requirements. For example, bupivacaine may be less suitable for day surgery procedures because of its greater failure rate, prolonged effect,2 and reportedly greater incidence of urinary retention, and chlorprocaine is not approved for use in spinal anesthesia.
Small-dose spinal lidocaine (15 mg), combined with 10 µg sufentanil, is associated with a very low incidence of transient neurological symptoms (TNS).3 In the consenting process, our patients were informed of the advantages and disadvantages of local anesthetics, including the incidence of TNS with different local anesthetics and different needles.
As we explained in the manuscript, for ethical reasons, the study was not completed because of the high incidence of TNS.
In conclusion, we do not believe that the intrathecal administration of lidocaine should be abandoned, but rather the injection technique and dosage should be improved, as suggested by our and other studies.4,5
REFERENCES
This article has been cited by other articles:
![]() |
D. D. Glass and A. D. Sessler Education in Anesthesiology Should Be Evidenced-Based Anesth. Analg., May 1, 2008; 106(5): 1588 - 1588. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|